{"prompt": "['ASSESSMENTS DURING TREATMENT (radiotherapy)', 'Assessment', 'Time Point', 'Assessment', 'Weekly', 'Last Week', 'History & Physical and', 'AE evaluation', 'X', 'Serum, plasma, and', 'urine (if patient consents)', 'X', 'See Section 10', 'ASSESSMENTS IN FOLLOW UP ARE TO BE SCHEDULED FROM THE START OF', 'RADIATION STARTING FROM 6 MONTHS', 'Assessment', 'End of', 'q 6', '1 year', '2 year', 'q 12', '5 years', 'Yearly', 'RT', 'months', 'months', 'after 5', 'during yrs', 'during', 'yrs', '1-2', 'yrs 3-5', 'Physical', 'exam with', 'X', 'X', 'X', 'DRE', 'Serum PSA', 'X', 'X', 'X', 'X', 'AE', 'X', 'X', 'X', 'X', 'evaluation', 'EPIC', 'X', 'X (only at', 'X', 'X', 'X', '(required)', '6 months)', 'EQ-5D', 'X', 'X (only at', 'X', 'X', 'X', '6 months)', 'Serum &', 'plasma (if', 'X', 'patient consents)', 'Definition of Disease Assessments', 'Biochemical failure: Two definitions of biochemical failure will be assessed:', 'Primary: PSA > 0.4 ng/mL and rising (i.e. PSA > 0.4 ng/mL followed by a value', 'higher than the first by any amount) or initiation of salvage hormones.', 'Alternate: PSA > PSA nadir + 2 ng/mL where nadir is the lowest post-RT PSA', 'level.', 'Local failure: development of a new biopsy-proven mass in the prostate bed, after', 'enrollment in the protocol.', 'NRG-GU003', '19', 'Version Date: April 26, 2019']['Regional failure: radiographic evidence (CT or MRI) of lymphadenopathy (lymph node', 'size > 1.0 cm in the short axis) in a patient without the diagnosis of a', 'hematologic/lymphomatous disorder associated with adenopathy.', 'Distant metastases: radiographic evidence of hematogenous spread (e.g., bone scan, CT,', 'MRI)', 'Progression: first occurrence of biochemical failure, local failure, regional failure, distant', 'metastasis, initiation of new unplanned anticancer treatment, or death from prostate', 'cancer.', '5. TREATMENT PLAN/REGIMEN DESCRIPTION', '5.1', 'Chemotherapy/Hormonal Therapy/Other Agent-Based Therapy', 'For patients receiving RT + androgen deprivation therapy (ADT), ADT may begin at any', 'time following Step I registration but prior to the start of RT. ADT prior to Step I', 'registration is allowed but, patient may have received prior ADT for up to 6 weeks (42', 'days) prior to Step 1 registration.', '5.1.1 Androgen Deprivation Therapy (ADT)', 'Any LHRH agonist/antagomist with or without an oral antiandrogen can be used;', 'however, ADT cannot be administered for more than a 6 month administration dose (i.e.', 'for Lupron this would be 45 mg, etc.). An oral antiandrogen alone cannot be used.', 'The total administered duration as well as the specific agent (s) used will be submitted on', 'the appropriate case report form.', '5.2', 'Radiation Therapy (26-APR-2019)', 'Start of Radiotherapy (RT)', 'For patients receiving RT alone (no androgen deprivation therapy [ADT]), RT must begin', 'within 4 weeks after Step 1 registration. For patients receiving RT+ADT, RT must begin', '8 weeks (plus or minus 1 week) after the first LHRH analog injection. Patient may have', 'received prior ADT up to 6 weeks (42 days) prior to Step 1 registration.', 'Radiation Therapy Schema', 'Schema at the beginning of the protocol should be followed.', '5.2.1', 'Treatment Technology', 'Photon energies ranging from \"Co to <18 MV are recommended. The following', 'techniques such as 3D CRT, IMRT, VMAT, Viewray, Cyberknife or Tomotherapy are', 'allowed.', '5.2.2', 'Immobilization and Simulation', 'Immobilization', 'Proper immobilization is critical for this protocol. Patient setup reproducibility must be achieved', 'NRG-GU003', '20', 'Version Date: April 26, 2019']\n\n###\n\n", "completion": "END"}